Galapagos NV (GLPG), a Belgium-based biotechnology pharmaceutical development company, recently agreed to a major deal with Gilead Sciences (GILD). Galapagos' stock got an immediate, massive price boost, while Gilead was little-affected. This interests me because a fair portion of my portfolio is invested in Gilead, which has not been a good performer these last few years, other than paying a hefty dividend.
This article is primarily about where I see value in the Galapagos clinical pipeline. I will also outline the Gilead deal. The thesis of this article is that the